Main Article Content


Cardiomyopathies are uncommon, although they are significant contributors to serious cardiovascular problems during pregnancy. Prior to pregnancy, it is crucial to have a thorough understanding of the potential dangers linked to cardiomyopathies and how to effectively treat them in pregnant women with significant pre-existing diseases. This knowledge is essential for providing appropriate guidance to patients. Given that all interventions relate to both the mother and the fetus, it is crucial to focus on providing the most efficient care for both. Maternal illness complicates pregnancy in approximately 1-4% of instances. There is a lack of comprehensive data on the frequency and occurrence of heart disease connected to pregnancy in most regions of the world including peripartum cardiomyopathy (PPCM) which was the predominant causes of maternal mortality in the UK in the mid of 2000’s. PPCM may result in persistent systolic dysfunction over an extended period of time. Although heart disease is a prominent, if not the primary, cause of death among pregnant or postpartum women across the country. PPCM is frequently misdiagnosed as a result of insufficient awareness among both medical professionals and the general public. The absence of an early and precise diagnosis of this ailment can have life-threatening implications for women affected by PPCM. Patients who had an early diagnosis saw a more expedited recovery compared to patients who received a late diagnosis. Improving the early monitoring, detection and diagnosis is linked to better recovery.

Article Details

How to Cite
Setyowati, D. U., Mayangsari, V., & Tjahjono, C. (2024). Peripartum Cardiomyopathy Management Strategies: An Evolving Challenge in Maternal Health . Jurnal Klinik Dan Riset Kesehatan, 3(3), 204-213.


1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J [Internet]. 2023;44(37):3503–626. Available from:
2. Setiantiningrum MH, Vallentino JE, Rehatta E. Penatalaksanaan Kardiomiopati Peripartum. Cdk. 2015;42(5):356–60.
3. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail. 2019;21(12):1534–42.
4. Hilfiker-Kleiner D, Haghikia A, Masuko D, Nonhoff J, Held D, Libhaber E, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail. 2017 Dec;19(12):1723–8.
5. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy. J Am Coll Cardiol [Internet]. 2020;75(2):207–21. Available from:
6. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397–409.
7. Setiantiningrum M, Rehatta V. Definisi, Etiopatogenesis, dan Diagnosis Kardiomiopati Peripartum. Cermin Dunia Kedokt 218. 2014;41(7):492–6.
8. Pachariyanon P, Bogabathina H, Jaisingh K, Modi M, Modi K. Long-Term Outcomes of Women With Peripartum Cardiomyopathy Having Subsequent Pregnancies. J Am Coll Cardiol [Internet]. 2023;82(1):16–26. Available from:
9. Sulistyanti D, Suryono B. Patofisiologi dan Penanganan Kardiomiopati Peripartum. J Anestesi Obstet Indones. 2020;2(2):108–21.
10. Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, et al. Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis. Curr Probl Cardiol [Internet]. 2023;48(2):101461. Available from:
11. Hönicke U, Albrecht S, Schrötter H, Krug S, Kolditz M, Kuhlisch E, et al. Prolactin and its 16-kDa N-terminal fragment: Are higher in patients with precapillary pulmonary hypertension than in a healthy control group. Texas Hear Inst J. 2012;39(1):44–9.
12. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell [Internet]. 2007;128(3):589–600. Available from:
13. Hilfiker-Kleiner D, Struman I, Hoch M, Podewski E, Sliwa K. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep. 2012 Sep;9(3):174–82.
14. Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. Texas Hear Inst J. 2012;39(1):8–16.
15. Tremblay-Gravel M, Marquis-Gravel G, Avram R, Desplantie O, Ducharme A, Bibas L, et al. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Hear Fail. 2019 Feb;6(1):27–36.
16. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail. 2019 Dec;21(12):1534–42.
17. Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: from genetics to management. Eur Heart J [Internet]. 2021;42(32):3094–102. Available from:
18. Spracklen TF, Chakafana G, Schwartz PJ, Kotta M-C, Shaboodien G, Ntusi NAB, et al. Genetics of Peripartum Cardiomyopathy: Current Knowledge, Future Directions and Clinical Implications. Genes (Basel). 2021 Jan;12(1).
19. Asad ZUA, Maiwand M, Farah F, Dasari TW. Peripartum cardiomyopathy: A systematic review of the literature. Clin Cardiol. 2018 May;41(5):693–7.
20. Cross M, Schirding JH, Domanski K. Peripartum Cardiomyopathy in a Multigravida Patient. Cureus. 2023;15(3):3–7.
21. Mezzetti E, Costantino A, Leoni M, Pieretti R, Di Paolo M, Frati P, et al. Autoimmune Heart Disease: A Comprehensive Summary for Forensic Practice. Med. 2023;59(8):1–52.
22. Reza N, Packard E, Goli R, Chowns JL, Owens AT, Arany Z, et al. Clinical Predictors of Referral for and Yield of Genetic Testing in Peripartum Cardiomyopathy. JACC Hear Fail [Internet]. 2023;11(9):1278–80. Available from:
23. Shimada BK, Alfulaij N, Seale LA. The impact of selenium deficiency on cardiovascular function. Int J Mol Sci. 2021;22(19).
24. Munguti CM, Al Rifai M, Shaheen W. A Rare Cause of Cardiomyopathy: A Case of Selenium Deficiency Causing Severe Cardiomyopathy that Improved on Supplementation. Vol. 9, Cureus. United States; 2017. p. e1627.
25. Prameswari HS, Purnomowati A, Aprami TM. Prevalence, Characteristics, andRisk Factor of Patient with Peripartum Cardiomyopathyin Hasan Sadikin Hospital Bandung. Indones J Cardiol. 2016;36(3):38–44.
26. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–78.
27. Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Card Fail Rev 2018;4(1)46–9 [Internet]. 2018; Available from:
28. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J [Internet]. 2018;39(34):3165–241. Available from:
29. Kim MJ, Shin MS. Practical management of peripartum cardiomyopathy. Korean J Intern Med. 2017;32(3):393–403.